oxybenzone

Small moleculeapproved

Approved

Dec 7, 1992

Oxybenzone is one of the more popular molecules used by chemists during the manufacturing of cosmetics and is included in sunscreen for UV protection. The chemical is often used to stabilize and strengthen the color and scent of skin care products, but its widest use is in the form of sun block. Unfortunately, the debate about the safety of oxybenzone is still ongoing. One of the biggest concerns in the medical community about the widespread use of the molecule comes from the fact that it’s easily absorbed into the body. This absorption raises concerns that oxybenzone may accumulate in the body, eventually leading to potentially toxic levels of the chemical, which can affect the endocrine system. — NCATS

Clinical trial activity

3 trials · 3 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 2012 (NCT01695356)

Timeline

1990s

Dec 7, 1992
Bayer — Earliest FDA Approval
Dec 7, 1992
Bayer — NDA Secondary Org
Dec 7, 1992
Bayer — NDA Organization

2010s

Jan 1, 2016
Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Unspecified targetOTHER
Sunscreen
Unspecified targetUltraviolet filter
ultraviolet filter

Combination products

shade uvaguar
with avobenzone, octinoxate

Approval history

approvedDec 7, 1992

Chemistry & pharmacology

Loading structure…

SMILES

COC1=CC=C(C(=O)C2=CC=CC=C2)C(O)=C1

Mol. weight: 228.2433 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Topical
Availability: Discontinued

Oral

Parenteral

Topical

Yes

Sources

Also known as

2-benzoyl-5-methoxyphenol
2-benzoyl-5-methoxyphenol
2-hydroxy-4-methoxybenzone
2-hydroxy-4-methoxybenzophenone
2-hydroxy-4-methoxybenzophenone
2-hydroxy-4-methoxybenzophenone
(2-hydroxy-4-methoxyphenyl)phenylmethanone
(2-hydroxy-4-methoxyphenyl)phenylmethanone
4-methoxy-2-hydroxybenzophenone
4-methoxy-2-hydroxybenzophenone
4-methoxy-2-hydroxybenzophenone butyric acid
4-methoxy-2-hydroxybenzophenone butyric acid
benzophenone-3
benzophenone-3
benzophenone-3
benzophenone-3
benzophenone-3
benzophenone-3
benzophenone-3
eusolex 4360
eusolex-4360
hmbp cpd
oxibenzona
oxibenzona
oxybenzon
oxybenzone
oxybenzone
oxybenzone
oxybenzone
oxybenzone
oxybenzone
oxybenzone
oxybenzonum
oxybenzonum
solbar
uvinul m40
uvinul m40

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03012347	N/A	Jan 1, 2017	Bayer
NCT02668536	Phase 1	Aug 1, 2016	Yale University
NCT01695356	Phase 4	Sep 1, 2012	Universidad Autonoma de San Luis Potosi

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Bayer	For profit	1	1	1	2017
Universidad Autonoma de San Luis Potosi	Academic/Hospital	1	1	1	2012
Yale University	Academic/Hospital	1	1	1	2016

3 organizations

Page 1 / 1

Marketing (2)

Organization	Org type	Relationship	Date
Bayer	For profit	NDA2	Dec 7, 1992
Bayer	For profit	NDA	Dec 7, 1992